(15)Commission Implementing Regulation (EU) 2023/2592note extended the approval period of the active substance difenoconazole until 15 March 2026, and the approval period of the active substance diflufenican until 15 January 2026.
Source: EUR-Lex, © European Union, 1998-2026. Reuse authorised under Decision 2011/833/EU.